Pathophysiology of Metastatic Bone Disease and the Role of Bisphosphonates

2/1/02


Click here to start


Table of Contents

Pathophysiology of Metastatic Bone Disease and the Role of Bisphosphonates

Clinical Importance and Prognosis of Bone Metastases

Skeletal Complications in Metastatic Bone Disease Are Significant

Pathophysiology of Bone Metastases

Cancer and Bone Cell Interactions

Bone Remodelling Cancer Effects

Bone Markers in Osteolytic and Osteosclerotic Metastatic Bone Disease

Consequences of Increased Bone Resorption

Treatment of Bone Metastases

Bisphosphonate Pharmacology

Prevention of Skeletal-Related Events Phase III Pamidronate Studies

Proportion of Patients Having SREs Pooled Breast Cancer Clinical Trials (N = 756)

Proportion of Patients Having SREs Multiple Myeloma (N = 377)

Total Number of SREs Recorded During Randomised Clinical Trials of Pamidronate

Effects of Pamidronate on Pain and Analgesic Consumption

Prostate Cancer and Other Tumours

PPT Slide

Adverse Events Profile of Pamidronate

Zoledronic Acid

PPT Slide

PPT Slide

ZOMETAŽ Key Clinical Pharmacology Properties

Phase II Study (007) Results Support ZOMETAŽ 4-mg Infusion Every 3 to 4 Wk

Urinary N-telopeptide/Creatinine Ratio After the First and Subsequent (q4 wk) Doses of ZOMETAŽ (Study 007)

Efficacy in Hypercalcaemia of Malignancy

Conclusions

Author: ssi